Fg-b901

Preclinical

FFutureGen Biopharmaceutical (Beijing) Co., Ltd

Fg-b901 is one of 2 therapeutic programs targeting Claudin 18.2. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Claudin 18.2Not yet recruiting

Claudin 18.2Preclinical

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Claudin 18.2

#DrugCompanyPhaseTrials

FG-M108

FFutureGen Biopharmaceutical (Beijing) Co., Ltd

Preclinical

1 2

Fg-b901

FFutureGen Biopharmaceutical (Beijing) Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalNot yet recruiting

Claudin 18.2

NCT07704866

Clinical

Trials by Indication[1]

Claudin 18.21 trial

An Open-Label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-M108 Injection in Combination With FG-B901 Injection in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors

Not yet recruiting·FFutureGen Biopharmaceutical (Beijing) Co., Ltd·Preclinical·NCT07704866·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fg-b901. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Fg-b901. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — FutureGen Biopharmaceutical (Beijing) Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: FFutureGen Biopharmaceutical (Beijing) Co., Ltd

Fg-b901

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Claudin 18.21 trial

References

Drug Info

Quick Facts

Related News